

Table S2: Plasmids used in this study

Name	Characteristics	Source
pVT100U	2 μ ADH URA3	(Vernet et al., 1987)
pVT100U mtALP	2 μ , ADH, URA3	This study
pVT100U cytALP	2 μ , ADH, URA3	This study
pVT100U mtGFP	2 μ , ADH, URA3	(Westermann and Neupert, 2000)
pYX242	2 μ , TPI, LEU2	Novagen
pYX242 mtALP	2 μ , TPI, LEU2	This study
pYX242 cytALP	2 μ , TPI, LEU2	This study
Yep213	2 μ , LEU2	(Otsuga et al., 1998)
Yep213 Dnm1a	2 μ , LEU2	(Otsuga et al., 1998)
Yep213 Dnm1 K41A	2 μ , LEU2	(Otsuga et al., 1998)
Yep213 Dnm1 S42N	2 μ , LEU2	(Otsuga et al., 1998)
pHS12 mtDsRed.T3	CEN, ADH, LEU2	(Bevis and Glick, 2002)
pRS316	CEN, URA3	(Sikorski and Hieter, 1989)
pRS316 GFP-Atg8	CEN, URA3	This study
pRS313 GFP-Atg8	CEN, HIS3	This study
pRS323 mtDsRed.T4	2 μ , TPI HIS3	(Jakobs et al., 2003)
pRS416 Fis1	CEN, URA3 515 bp 5'-UTR & 238 bp 3'-UTR from FIS1	This study
YPlac33 WHI2	CEN, URA3, 5'-UTR WHI2	(Cheng et al., 2008)
pVT100U WHI2-His	2 μ ADH URA3	This study